Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ: KYMR )

40.66 +1.52 (+3.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher
U.S. stocks traded slightly higher toward the end of trading on Tuesday. 
Via Benzinga
Why Kymera Therapeutics Shares Are Falling Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday. 
Via Benzinga
41 Stocks Moving In Tuesday's Mid-Day Session
Gainers SoundHound AI, Inc. (NASDAQ: SOUN) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma... 
Via Benzinga
Kymera Therapeutics: Q1 Earnings Insights
Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Ratings for Kymera Therapeutics
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET
Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474
JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58... 
Via Benzinga
Kymera Discloses New Development Cancer Program
Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to... 
Via Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ: 
Via Benzinga
The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
Kymera Prices $223M Equity Offering At $47/Share
Kymera Therapeutics Inc (NASDAQ: KYMR) has priced its upsized underwritten public offering of 4.7 million shares at $47.00 per share, representing a discount... 
Via Benzinga
31 Stocks Moving in Wednesday's Pre-Market Session
Gainers Bridgeline Digital, Inc. (NASDAQ: BLIN) shares rose 83% to $6.20 in pre-market trading. Bridgeline Digital shares jumped over 36% on Tuesday on above-average volume.... 
Via Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises
Kymera Therapeutics Inc (NASDAQ: KYMR) commenced an underwritten public offering of 4 million shares of common stock. Underwriters can purchase up to an... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
72 Biggest Movers From Yesterday
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers
Kymera Therapeutics Inc (NASDAQ: KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy... 
Via Benzinga
51 Stocks Moving In Wednesday's Mid-Day Session
Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6... 
Via Benzinga
Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity
Kymera Therapeutics Inc (NASDAQ: KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.